Phase III trial for KLU156 (ganaplacide/lumefantrine, or GanLum), meets primary endpoint of non-inferiority to standard of care Coartem® (artemether-lumefantrine) Demonstrates PCR-corrected cure rate ...
First to have delivered at scale, Novartis fortifies leadership in RLT innovation and infrastructure with California facility, additional plans for Florida and Texas ...
Explore opportunities with Novartis and Sandoz below. For additional roles with Novartis Gene Therapies (formerly AveXis) visit the GTx Career Search.
Sports have a universal appeal that transcends boundaries. Each weekend, the NFL ignites millions of passionate fans from across the country, demonstrating the deep connection and power of community.
At Novartis, we innovate, develop and operate on a vast scale. You can be part of it. Join our creative community of professionals and you will find opportunities to make an unprecedented impact – on ...
Novartis has had a significant footprint in India since 1947, with two legal entities namely, Novartis Healthcare Private Limited, and Novartis India Limited. India is amongst a handful of countries ...
Ad hoc announcement pursuant to Art. 53 LR NEPTUNUS-1 and NEPTUNUS-2 are the first ever global phase III trials to demonstrate statistically significant reduction in disease activity for Sjögren’s ...
Puede explorar más oportunidades con Novartis y Sandoz, aquí. Para vacantes adicionales de Terapias Génicas (antes AveXis) visita la busqueda de vacantes específica.
Select units of Cosentyx to be made available at 55% discount off list price on direct-to-patient (DTP) platform beginning November 1, 2025 DTP offering to expand to other appropriate products; ...
Metastatic prostate cancer has a 5-year survival rate of less than 30% 3; mCRPC patients who progress on multiple lines of therapy have limited treatment options FDA approval was based on pivotal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback